Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$6.41	$5.25	$1.62 ▼ $7.27	$571.39M	-0.49	1.19 million shs	2.02 million shs
HRTX Heron Therapeutics	$2.17 +4.8%	$2.06	$1.04 ▼ $3.73	$315.81M	1.18	2.20 million shs	2.29 million shs
NGNE Neurogene	$19.19 +28.4%	$17.49	$6.88 ▼ $74.49	$213.22M	1.51	249,856 shs	1.35 million shs
OPTN OptiNose	$9.60	$9.53	$4.82 ▼ $19.50	$97.22M	-0.88	62,399 shs	N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	0.00%	+22.56%	+69.58%	+240.96%
HRTX Heron Therapeutics	+4.83%	+0.93%	+14.81%	-2.69%	-37.46%
NGNE Neurogene	+28.36%	+11.57%	+11.50%	+83.46%	-52.76%
OPTN OptiNose	0.00%	0.00%	0.00%	+4.80%	-39.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.5156 of 5 stars	4.5	2.0	0.0	2.5	2.5	0.6
HRTX Heron Therapeutics	4.0234 of 5 stars	3.5	0.0	4.2	3.9	1.7	0.6
NGNE Neurogene	3.5168 of 5 stars	4.4	3.0	0.0	1.4	1.7	1.3
OPTN OptiNose	0.6862 of 5 stars	1.0	0.0	4.2	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	2.92	Moderate Buy	$11.00	71.61% Upside
HRTX Heron Therapeutics	3.00	Buy	$5.00	130.41% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	140.58% Upside
OPTN OptiNose	2.00	Hold	$9.00	-6.25% Downside

Current Analyst Ratings Breakdown

Latest OPTN, HRTX, AMLX, and NGNE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00
6/17/2025	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/30/2025	AMLX Amylyx Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/20/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
5/19/2025	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$9.00 ➝ $9.00
5/16/2025	NGNE Neurogene	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	6.54	N/A	N/A	$2.40 per share	2.67
HRTX Heron Therapeutics	$144.29M	2.29	N/A	N/A	($0.22) per share	-9.86
NGNE Neurogene	$930K	294.25	N/A	N/A	$20.89 per share	0.92
OPTN OptiNose	$81.86M	1.19	N/A	N/A	($11.56) per share	-0.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$301.74M	-$3.11	N/A	N/A	N/A	N/A	-77.21%	-63.84%	8/6/2025 (Estimated)
HRTX Heron Therapeutics	-$13.58M	-$0.06	N/A	N/A	N/A	-5.24%	N/A	-3.43%	8/5/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.35	N/A	N/A	N/A	N/A	-36.16%	-32.51%	8/8/2025 (Estimated)
OPTN OptiNose	-$35.48M	-$3.00	N/A	N/A	N/A	-41.16%	N/A	-27.42%	8/6/2025 (Estimated)

Latest OPTN, HRTX, AMLX, and NGNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	OPTN OptiNose	-$0.74	-$1.01	-$0.27	-$1.92	$17.70 million	$18.51 million
5/9/2025	Q1 2025	NGNE Neurogene	-$1.05	-$1.08	-$0.03	-$1.08	N/A	N/A
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.45	-$0.42	+$0.03	-$0.42	N/A	N/A
5/6/2025	Q1 2025	HRTX Heron Therapeutics	-$0.01	$0.01	+$0.02	$0.01	$37.08 million	$38.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.05	12.05
HRTX Heron Therapeutics	N/A	2.40	1.76
NGNE Neurogene	N/A	21.03	21.03
OPTN OptiNose	N/A	0.79	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
HRTX Heron Therapeutics	80.01%
NGNE Neurogene	52.37%
OPTN OptiNose	85.60%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
HRTX Heron Therapeutics	5.86%
NGNE Neurogene	9.92%
OPTN OptiNose	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.14 million	78.71 million	Optionable
HRTX Heron Therapeutics	300	152.56 million	143.62 million	Optionable
NGNE Neurogene	90	14.26 million	12.85 million	Optionable
OPTN OptiNose	190	10.13 million	9.83 million	Not Optionable

OPTN, HRTX, AMLX, and NGNE Headlines

Recent News About These Companies

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

May 21, 2025 | finance.yahoo.com

Optinose Stockholders Approve Merger with Paratek

May 16, 2025 | tipranks.com

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

May 14, 2025 | zacks.com

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN

April 29, 2025 | businesswire.com

Optinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational Income

March 28, 2025 | msn.com

Optinose reports Q4 EPS (3c) vs ($1.33) last year

March 27, 2025 | markets.businessinsider.com

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

March 26, 2025 | markets.businessinsider.com

OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates

March 26, 2025 | zacks.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of Shareholders

March 25, 2025 | morningstar.comM

Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to Trade

March 24, 2025 | zacks.com

Optinose downgraded to Neutral from Buy at H.C. Wainwright

March 22, 2025 | markets.businessinsider.com

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN

March 21, 2025 | businesswire.com

OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek

March 21, 2025 | zacks.com

Optinose downgraded to Neutral from Overweight at Piper Sandler

March 21, 2025 | markets.businessinsider.com

Optinose downgraded to Hold from Buy at Lake Street

March 21, 2025 | markets.businessinsider.com

Lake Street Downgrades OptiNose (OPTN)

March 21, 2025 | msn.com

Why OptiNose Inc. (OPTN) Surged On Thursday?

March 21, 2025 | msn.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders

March 21, 2025 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTN

March 20, 2025 | gurufocus.com

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTN

March 20, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPTN, HRTX, AMLX, and NGNE Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$6.41 0.00 (0.00%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$6.42 +0.00 (+0.08%)

As of 05:57 AM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Heron Therapeutics NASDAQ:HRTX

$2.17 +0.10 (+4.83%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$2.24 +0.06 (+3.00%)

As of 05:20 AM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Neurogene NASDAQ:NGNE

$19.19 +4.24 (+28.36%)

Closing price 07/1/2025 04:00 PM Eastern

Extended Trading

$19.23 +0.04 (+0.21%)

As of 06:23 AM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

OptiNose NASDAQ:OPTN

$9.60 0.00 (0.00%)

As of 05/21/2025

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time